ClinicalTrials.gg
TerminatedNCT01375179Updated Feb 11, 2020

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

A Phase 2 interventional study of KRP203 and Placebo matching KRP203 in Ulcerative Colitis, sponsored by Novartis Pharmaceuticals. Terminated at 14 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-02-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 243 studies in Colitis, Ulcerative with a site in Germany — 29 open to participants now, 62 under way, 26 of them phase 3. Colitis, Ulcerative · Germany.

Enrollment
183rd of 202
27 · median 179
Started
2010
with 3 others
Phase 2
79 of 243
7 open now
Registered
44th of 243
by date

Among the 243 studies in Colitis, Ulcerative with a site in Germany, this one is the 183rd largest by enrollment of the 202 interventional ones that give a count, is one of 4 that started in 2010, is one of 79 in phase 2, and was the 44th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

29 of the 243 studies in Colitis, Ulcerative with a site in Germany are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 243 studies in Colitis, Ulcerative with a site in Germany, or all of them as a file.
02

Study summary

This study is designed as a proof of concept of KRP203 for induction of remission in ulcerative colitis (UC). The purpose of this study is to evaluate clinical benefit of KRP203 in subjects with moderately active refractory ulcerative colitis.

The study will provide safety and tolerability data in this subject population up to eight weeks of treatment with KRP203. Additionally, this study will evaluate the duration of a clinical response to KRP203 by following up responding subjects for an additional 12 weeks.

Read the detailed description

This is a multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ulcerative colitis subjects. In total, approximately 72 subjects will be randomized into the study.

After 30 patients have completed the 8 week treatment period with KRP203 or placebo, there will be an interim analysis to determine preliminary efficacy. The study will consist of up to 28 day screening period (day -35 to -8), baseline period (day -7 to day -1), treatment period (day 1 to day 56), follow-up period and study completion.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Inflammatory Bowel disease
  • Ulcerative colitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active disease defined by partial Mayo score and modified Baron score with disease extending at least 25 cm from the anal verge
  • Subjects must have inadequately responded or intolerance to 5-ASA therapy

Exclusion criteria

Exclusion Criteria:

  • Subjects receiving treatment for UC (other than 5-ASAs and ) within the time frame mentioned in protocol
  • Past or recent history of significant medical illness and/or lab abnormalities including but not limited to hematology, clinical chemistry, urine analysis, abnormalities, , /C
  • Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, ophthalmic, cardiac, blood, renal, hepatic, infectious, psychiatric or any medically unstable condition, as assessed by the primary treating physician which, in the opinion of the investigator, would immunocompromise the subject and/or place the subject at unacceptable risk for participation in a study of an immunomodulatory therapy Other protocol-defined inclusion/exclusion criteria apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    KRP203

    Experimental Edit Experimental

    Drug: KRP203

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo matching KRP203

Interventions

  • DrugKRP203
  • DrugPlacebo matching KRP203
06

What researchers measure

Primary outcomes

  1. Change in clinical remission rate

    Difference between clinical remission rate of subjects on KRP203 versus placebo

    Time frame: 8 weeks

Secondary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Safety and tolerability of KRP203 assessed by the number of subjects with adverse events where KRP203 is given as an oral drug for 8 weeks once a day in ulcerative colitis subjects

    Time frame: 8 weeks

  2. Pharmacokinetic properties of KRP203 at steady-state using whole blood samples in patients with ulcerative colitis subjects

    Time frame: 8 weeks

  3. Difference in pharmacokinetic levels

    To explore the relationship between KRP203 and KRP203-P pharmacokinetic levels and clinical efficacy outcomes such as the partial Mayo score and endoscopic modified Baron Score

    Time frame: 12 weeks

  4. Assessment of the pharmacodynamic effect of KRP203 on absolute lymphocyte count and leukocyte subsets in ulcerative colitis subjects

    Time frame: 12 weeks

  5. Change in markers of inflammation

    Measure of the effect of KRP203 on markers of inflammation, including but not limited to ESR, CRP and fecal calprotectin/ lactoferrin as well as histopathological markers of gut mucosa using biopsy samples in ulcerative colitis subjects

    Time frame: 12 weeks

07

Study locations

14 sites
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Frankfurt am Main, 60318, Germany
  • Novartis Investigative Site
    Hamburg, 20148, Germany
  • Novartis Investigative Site
    Köln, 51103, Germany
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Stockholm, 116 91, Sweden
  • Novartis Investigative Site
    Stockholm, SE-141 86, Sweden
  • Novartis Investigative Site
    Uppsala, 751 85, Sweden
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Oxford, Oxfordshire OX3 9DU, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG7 2UH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2011
First posted
Jun 17, 2011
Start
Dec 2010
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
Feb 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01375179
Responsible party
Sponsor
First posted
Jun 17, 2011
Start date
Dec 2010
Primary completion
May 2012
Completion
May 2012
Last update
Feb 11, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRP-203

Start the discussion